Table 2. Overview of nine genes showing significantly different DGE in post-exposure relative to pre-exposure samples.
| Males | Females | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| treatment | mRNA species | n (pre-exposure) | n (60 days after irr.) | mean Ct-value (pre-exposure) | mean Ct-value (60 days after irr.) | Fold-change | p-value | ROC | n (pre-exposure) | n (60 days after irr.) | mean Ct-value (pre-exposure) | mean Ct-value (60 days after irr.) | Fold-change | p-value | ROC |
| without treatment | CD248 | 14 | 1 | 15.3 | 17.8 | 0.2 | 1.0 | 22 | 2 | 15.5 | 17.7 | 0.2 | 0.08 | 0.91 | |
| with treatment, IL-12 | 1 | 3 | 15.1 | 17.7 | 0.2 | 1.0 | 5 | 1 | 14.8 | 17.7 | 0.1 | 1.0 | |||
| with treatment, IL-12+G-CSF | 18 | 3 | 15.0 | 17.8 | 0.1 | 0.002 | 1.0 | 9 | 2 | 14.4 | 16.0 | 0.3 | 0.027 | 0.94 | |
| all | 33 | 7 | 15.1 | 17.8 | 0.2 | <0.0001 | 1.0 | 36 | 5 | 15.1 | 16.7 | 0.3 | 0.003 | 0.87 | |
| without treatment | EDAR | 16 | 2 | 13.6 | 17.6 | 0.1 | 0.002 | 1.0 | 22 | 3 | 13.3 | 15.4 | 0.2 | 0.0002 | 0.99 |
| with treatment, IL-12 | 1 | 5 | 12.5 | 16.5 | 0.1 | 1.0 | 5 | 3 | 13.6 | 17.5 | 0.1 | 0.0001 | 1.0 | ||
| with treatment, IL-12+G-CSF | 18 | 8 | 13.38 | 17.38 | 0.1 | <0.0001 | 1.0 | 9 | 3 | 13.1 | 16.2 | 0.1 | 0.001 | 1.0 | |
| all | 35 | 15 | 13.5 | 17.1 | 0.1 | <0.0001 | 0.99 | 36 | 9 | 13.3 | 16.4 | 0.1 | <0.0001 | 0.99 | |
| without treatment | FAM19A5 | 15 | 3 | 15.16 | 17.3 | 0.2 | 0.08 | 0.87 | 17 | 2 | 15.9 | 16.7 | 0.6 | 0.4 | 0.69 |
| with treatment, IL-12 | 1 | 5 | 12.5 | 16.1 | 0.1 | 1.0 | 3 | 3 | 17.2 | 17.1 | 1.0 | 0.95 | 0.5 | ||
| with treatment, IL-12+G-CSF | 15 | 9 | 15.9 | 17.1 | 0.4 | 0.012 | 0.83 | 8 | 3 | 15.2 | 17.1 | 0.3 | 0.11 | 0.88 | |
| all | 31 | 17 | 15.4 | 16.9 | 0.4 | 0.0021 | 0.78 | 28 | 8 | 15.8 | 17.0 | 0.4 | 0.004 | 0.75 | |
| without treatment | GAL3ST4 | 16 | 2 | 14.2 | 17.6 | 0.1 | 0.08 | 1.0 | 22 | 2 | 14.4 | 15.7 | 0.4 | 0.07 | 1.0 |
| with treatment, IL-12 | 1 | 4 | 13.95 | 17.4 | 0.1 | 1.0 | 5 | 1 | 14.9 | 17.1 | 0.2 | 1.0 | |||
| with treatment, IL-12+G-CSF | 18 | 5 | 14.8 | 17.5 | 0.2 | <0.0001 | 0.99 | 9 | 3 | 14.1 | 16.2 | 0.2 | 0.15 | ||
| all | 35 | 11 | 14.5 | 17.5 | 0.1 | <0.0001 | 0.99 | 36 | 6 | 14.4 | 16.2 | 0.3 | <0.0001 | 0.92 | |
| without treatment | GCNT4 | 17 | 6 | 11.2 | 15.4 | 0.1 | <0.0001 | 1.0 | 23 | 3 | 11.3 | 12.9 | 0.3 | 0.095 | 0.94 |
| with treatment, IL-12 | 1 | 6 | 9.9 | 14.3 | 0.0 | 1.0 | 5 | 3 | 11.0 | 15.2 | 0.1 | <0.0001 | 1.0 | ||
| with treatment, IL-12+G-CSF | 18 | 14 | 11.1 | 14.9 | 0.1 | <0.0001 | 1.0 | 9 | 6 | 10.6 | 14.9 | 0.1 | 0.004 | 1.0 | |
| all | 36 | 26 | 11.1 | 14.9 | 0.1 | <0.0001 | 37 | 12 | 11.1 | 14.5 | 0.1 | <0.0001 | 0.96 | ||
| without treatment | HBG2_HBG1 | 18 | 6 | 10.18 | 5.17 | 32.2 | 0.002 | 0.91 | 23 | 3 | 8.5 | 10.6 | 0.2 | 0.1 | 0.87 |
| with treatment, IL-12 | 1 | 6 | 7.5 | 5 | 5.7 | 5 | 3 | 9.8 | 4.8 | 32.0 | 0.035 | 1.0 | |||
| with treatment, IL-12+G-CSF | 18 | 14 | 8.75 | 6.6 | 4.4 | 0.0025 | 0.86 | 9 | 6 | 9.1 | 5.5 | 12.1 | 0.048 | 0.83 | |
| all | 37 | 26 | 9.4 | 5.9 | 11.3 | <0.0001 | 0.86 | 37 | 12 | 8.8 | 6.6 | 4.6 | 0.07 | 0.68 | |
| without treatment | LRRN1 | 21 | 5 | 12.24 | 15.52 | 0.1 | 0.0008 | 0.93 | 22 | 3 | 12.2 | 15.0 | 0.1 | 0.005 | 0.94 |
| with treatment, IL-12 | 1 | 6 | 12 | 14.95 | 0.1 | 0.83 | 5 | 3 | 12.6 | 14.6 | 0.3 | 0.029 | 1.0 | ||
| with treatment, IL-12+G-CSF | 18 | 11 | 12.8 | 16.3 | 0.1 | <0.0001 | 0.99 | 9 | 5 | 12.5 | 14.8 | 0.2 | 0.014 | 0.89 | |
| all | 40 | 22 | 12.5 | 15.77 | 0.1 | <0.0001 | 0.94 | 36 | 11 | 12.3 | 14.8 | 0.2 | <0.0001 | 0.92 | |
| without treatment | NOG | 20 | 6 | 11.64 | 15.96 | 0.1 | <0.0001 | 1.0 | 23 | 3 | 11.6 | 13.3 | 0.3 | 0.049 | 0.96 |
| with treatment, IL-12 | 1 | 6 | 10.8 | 15.5 | 0.0 | 1.0 | 5 | 3 | 11.5 | 16.1 | 0.0 | 0.0002 | 1.0 | ||
| with treatment, IL-12+G-CSF | 18 | 14 | 11.3 | 15.5 | 0.1 | <0.0001 | 1.0 | 9 | 6 | 10.7 | 15.2 | 0.0 | 0.004 | ||
| all | 39 | 26 | 11.4 | 15.4 | 0.1 | <0.0001 | 37 | 12 | 11.3 | 15.0 | 0.1 | <0.0001 | 0.96 | ||
| without treatment | SYT14 | 15 | 1 | 16.04 | 17.69 | 0.3 | 22 | 2 | 15.5 | 16.8 | 0.4 | 0.15 | 0.86 | ||
| with treatment, IL-12 | 1 | 2 | 15.5 | 16.4 | 0.5 | 1.0 | 5 | 1 | 15.8 | 18.0 | 0.2 | 1.0 | |||
| with treatment, IL-12+G-CSF | 18 | 4 | 15.9 | 17.2 | 0.4 | 0.008 | 0.9 | 9 | 3 | 15.4 | 16.2 | 0.6 | 0.2 | 0.72 | |
| all | 34 | 7 | 16 | 17.1 | 0.5 | 0.011 | 36 | 6 | 15.5 | 16.7 | 0.4 | 0.016 | 0.8 | ||
Overview of nine genes that were significantly different in post-exposure relative to pre-exposure samples and expressed in ≥ 50% of samples per group. Data are presented separately for male (left part) and female rhesus macaques (right part) and ordered starting with untreated, treated (IL-12 and IL-12 + G-CSF), and untreated and treated groups combined (all). The number of measurements and the mean gene expression (threshold cycle, Ct) values are provided by pre- and post-exposure samples as well as the fold-change difference (derived from Ct-values applying the ΔΔ-Ct-approach). For instance, fold-changes of 0.1 or 10 are referring to a 10-fold down-regulation or up-regulation, respectively. A t-test was applied for this group comparison. P-values (chisquare statistic) of the category “all” are presented in bold when surviving Bonferroni correction for multiple comparison. ROC areas were derived from logistic regression analysis.